55 Recruiting Myelofibrosis Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Top Recruiting Myelofibrosis Studies
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
📍 University of Alabama At Birmingham — Birmingham, Alabama
View Study & Checklist ➔Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
📍 UC Davis Health — Sacramento, California
View Study & Checklist ➔Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis
📍 Tom Baker Cancer Centre — Calgary, Alberta
View Study & Checklist ➔Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
📍 UAB Division of Hematology/Oncology — Birmingham, Alabama
View Study & Checklist ➔Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔AlloHCT With PegINFa for Myelofibrosis
📍 Huntsman Cancer Institute at the University of Utah — Salt Lake City, Utah
View Study & Checklist ➔Therapeutic RSK1 Targeting in Myelofibrosis
📍 Washington University School of Medicine — St Louis, Missouri
View Study & Checklist ➔A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
📍 University of Alabama — Birmingham, Alabama
View Study & Checklist ➔A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
📍 Massachusetts General Hospital (Data Collection Only) — Boston, Massachusetts
View Study & Checklist ➔A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
📍 The Oncology Institute of Hope and Innovation — Pasadena, California
View Study & Checklist ➔Momelotinib During and After HCT in Myelofibrosis
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Checklist ➔Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)
📍 Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
View Study & Checklist ➔Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
📍 The University of Kansas Cancer Center-Westwood — Westwood, Kansas
View Study & Checklist ➔Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
📍 UAB Hospital — Birmingham, Alabama
View Study & Checklist ➔A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
📍 Local Institution - 0069 — Newport Beach, California
View Study & Checklist ➔A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
📍 University of California-San Diego/Moores UCSD Cancer Center — La Jolla, California
View Study & Checklist ➔Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
📍 Center for International Blood and Marrow Transplant Research — Minneapolis, Minnesota
View Study & Checklist ➔Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
📍 Chao Family Comprehensive Cancer Center, University of California, Irvine — Orange, California
View Study & Checklist ➔Revumenib in Patients With Myelofibrosis
📍 Icahn School of Medicine at the Mount Sinai Hospital — New York, New York
View Study & Checklist ➔A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
View Study & Checklist ➔A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
📍 City of Hope — Duarte, California
View Study & Checklist ➔A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis
📍 MD Andersson Cancer Hospital — Houston, Texas
View Study & Checklist ➔A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
📍 City of Hope - Duarte Main Site — Duarte, California
View Study & Checklist ➔Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)
📍 Thomas Jefferson University — Philadelphia, Pennsylvania
View Study & Checklist ➔A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis
📍 Memorial Sloan Kettering Monmouth — Middletown, New Jersey
View Study & Checklist ➔Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
📍 Icahn School of Medicine at Mount Sinai — New York, New York
View Study & Checklist ➔Quantitative MRI for Myelofibrosis
📍 University of Michigan Hospital — Ann Arbor, Michigan
View Study & Checklist ➔Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔